January 10, 2017
Uncertainty has emerged over whether MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) will be able to continue meeting all four criteria for the sakigake fast-track designation it clinched in 2015 after Ono Pharmaceutical filed its rival med Opdivo (nivolumab) for a gastric...read more